Search Results for "Surgery"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Surgery. Results 51 to 60 of 252 total matches.

Intravenous Acetaminophen (Ofirmev)

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2011  (Issue 1361)
surgery in 244 patients, IV acetaminophen 650 mg every 4 hours significantly reduced pain and rescue use ...
The FDA has approved an intravenous (IV) formulation of acetaminophen (Ofirmev – Cadence) for use in patients ≥2 years old for management of pain either as monotherapy (mild to moderate pain) or with an opioid (moderate to severe pain) and for reduction of fever.
Med Lett Drugs Ther. 2011 Apr 4;53(1361):26-8 |  Show IntroductionHide Introduction

Uterine Artery Embolization for Fibroids

   
The Medical Letter on Drugs and Therapeutics • Apr 11, 2005  (Issue 1206)
Publication SUMMARY – UAE is an alternative to surgery for treatment of uterine fibroids that uses injections ...
Uterine artery embolization (UAE) is an increasingly used alternative to surgery for treatment of uterine fibroids.
Med Lett Drugs Ther. 2005 Apr 11;47(1206):31-2 |  Show IntroductionHide Introduction

Obalon Balloon System - Another Gastric Balloon for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2017  (Issue 1523)
nerve signals between the stomach and the brain, is less effective than bariatric surgery.3 ...
The FDA has approved the Obalon Balloon System (Obalon), a swallowable intragastric gas-filled balloon device, to facilitate weight loss in adults with a body mass index (BMI) of 30-40 kg/m2 who have not been able to lose weight through diet and exercise. Two other gastric balloon devices, ReShape and Orbera, were approved earlier.
Med Lett Drugs Ther. 2017 Jun 19;59(1523):102-3 |  Show IntroductionHide Introduction

Maestro Rechargeable System for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016  (Issue 1493)
and intra-abdominal surgery occurred in 8.6% of patients.4 Pain at the neuroregulator site occurred ...
The FDA has approved the Maestro Rechargeable System (EnteroMedics), a subcutaneously implanted device, for use in adults who have not been able to lose weight with a weight loss program within the past 5 years and who have a body mass index (BMI) of 40 to 45, or a BMI ≥35 and at least one obesity-related comorbidity.
Med Lett Drugs Ther. 2016 Apr 25;58(1493):54-5 |  Show IntroductionHide Introduction

ReShape and Orbera - Two Gastric Balloon Devices for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Aug 31, 2015  (Issue 1476)
. CONTRAINDICATIONS — Both devices are contraindicated in patients who have had gastrointestinal surgery or open ...
The FDA has approved the ReShape Integrated Dual Balloon System (ReShape Medical) and the Orbera Intragastric Balloon System (Apollo Endosurgery) for up to 6 months of use in adults with a BMI of 30-40 who have not been able to maintain weight loss with a weight loss program and, for ReShape, who have at least one obesity-related comorbidity. Both devices have been available in the European Union and elsewhere for years (20 years for Orbera). Three other devices, the LAP-Band, the Realize adjustable gastric band, and the Maestro Rechargeable System, are FDA-approved for long-term...
Med Lett Drugs Ther. 2015 Aug 31;57(1476):122-3 |  Show IntroductionHide Introduction

Ciprofloxacin (Otiprio) for Tympanostomy Tube Insertion

   
The Medical Letter on Drugs and Therapeutics • May 23, 2016  (Issue 1495)
as otorrhea ≥3 days after surgery, need for antibiotics for any reason at any time post-surgery, or a missed ...
The FDA has approved ciprofloxacin 6% otic suspension (Otiprio – Otonomy) for single-dose prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement. It is the first drug to be approved for this indication in the US. Otic formulations of the fluoroquinolone antibiotics ofloxacin (Floxin Otic, and generics) and ciprofloxacin (plus dexamethasone; Ciprodex) have been available for years for treatment of acute otitis media in children with tympanostomy tubes; an otic suspension containing ciprofloxacin and fluocinolone...
Med Lett Drugs Ther. 2016 May 23;58(1495):69-70 |  Show IntroductionHide Introduction

Desflurane - A New Volatile Anesthetic

   
The Medical Letter on Drugs and Therapeutics • Apr 30, 1993  (Issue 895)
of desflurane can be changed rapidly as stimulus levels change during surgery. In one study, recovery took ...
Desflurane (Suprane - Anaquest), an inhalation anesthetic, has been approved by the US Food and Drug Administration for induction and maintenance of general anesthesia in adults and for maintenance of anesthesia in infants and children. Like isoflurane (Forane), the last volatile anesthetic to become available in the USA (Medical Letter, 23:112, 1981), the new agent is a halogenated methyl ethyl ether, differing from isoflurane in the substitution of a fluorine for a chlorine atom.
Med Lett Drugs Ther. 1993 Apr 30;35(895):38-9 |  Show IntroductionHide Introduction

Cosmetic Phalloplasty

   
The Medical Letter on Drugs and Therapeutics • May 24, 2004  (Issue 1183)
reconstructive surgery for these complications (H Wessells et al, J Urol 1996; 155:1617; GJ Alter J Urol 1997 ...
Some patients may be asking healthcare providers about the surgical techniques to enlarge the penis that are widely promoted on the Internet. Phalloplasty was first used to treat traumatic or surgical amputation (for cancer), epispadias and Peyronie's disease (JP Yurkanin et al, J Urol 2001; 166:1769).
Med Lett Drugs Ther. 2004 May 24;46(1183):44 |  Show IntroductionHide Introduction

In Brief: New FDA Warning of Pulmonary Aspiration with GLP-1 Receptor Agonists

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024  (Issue 1718)
recommended withholding GLP-1 receptor agonists on the day of elective surgery for those ...
The package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity), exenatide (Byetta, Bydureon BCise), liraglutide (Saxenda, Victoza), and semaglutide (Ozempic, Rybelsus, Wegovy) and the dual glucosedependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) have been updated to include rare postmarketing reports of pulmonary aspiration associated with their use in patients undergoing elective surgery or other procedures requiring general anesthesia or deep sedation who had residual gastric contents despite preoperative...
Med Lett Drugs Ther. 2024 Dec 23;66(1718):201-2   doi:10.58347/tml.2024.1718a |  Show IntroductionHide Introduction

Enoxaparin - A Low-Molecular-Weight Heparin

   
The Medical Letter on Drugs and Therapeutics • Aug 20, 1993  (Issue 903)
-analysis of studies involving more than 8000 patients undergoing orthopedic surgery found ...
Enoxaparin (Lovenox - Rh ne-Poulenc Rorer), the first low-molecular-weight heparin to become commercially available in the USA, was recently approved by the US Food and Drug Administration for prevention of deep vein thrombosis following hip replacement. Five other products have been marketed in Europe.
Med Lett Drugs Ther. 1993 Aug 20;35(903):75-6 |  Show IntroductionHide Introduction